Pain is considered one factor of maternal morbidity not only in the postoperative period but also during the antenatal period in the form of pelvic pain. Although the pelvic pain present during the antenatal period is not harmful to either the mother or fetus, various measures have been described to make the gestational and puerpereal periods tolerable and satisfying to both the mother and family (
13). Recent techniques for postoperative management in abdominal surgeries include ultrasound-guided TAP block, which has produced promising results (
14). Similarly, TAP blocks are effectively used for post-caesarean analgesia (
15). Providing high-quality analgesia is of paramount importance in developing countries and in all hospital settings. Therefore, intrathecal adjuvants are one of the easiest and most accessible methods of offering pain relief.
Midazolam is a relatively water-soluble benzodiazepine (
16) and is extensively used in both critical care medicine and in the operating room for its sedative, anxiolytic, and amnesic effects (
6). Another relatively newer concept for intrathecal midazolam in anesthesia practice is as an adjuvant. Midazolam exerts its analgesic activity through benzodiazepine receptors, which are distributed in the gray matter of the cervical, thoracic, lumbar, and sacral regions of the spinal cord; the highest densities of receptors were localized within lamina II of the dorsal horn (
17). The segmental analgesia produced by intrathecal midazolam is mediated by the benzodiazepine GABA receptor complex, which is also involved in other benzodiazepine actions (
18).
It has further been argued that intrathecal midazolam reduces excitatory GABA-mediated neurotransmission in interneurons, leading to a decrease in the excitability of spinal dorsal horn neurons (
19). In animal studies, research has shown that intrathecal midazolam increases the pain threshold by binding to benzodiazepine receptors in the spinal cord (
20-
23). One study (
24) reported that when 2 mg intrathecal midazolam were added to 1.5 mL of 5% lignocaine in women who underwent a caesarean section delivery, postoperative pain relief was evident. A similar result was shown by Tucker and colleagues (
25). The first reports of spinal midazolam in the peer-reviewed literature were by Niv et al. (
26), who showed a reduction in small afferent-evoked somatosympathetic reflexes in anesthetized dogs with no effect on the resting arterial blood pressure. On the basis of the appreciation of the role of GABA in regulating motor tone, Muller et al. (
27) reported an antispasticity effect of intrathecal midazolam in unanesthetized, spinally catheterized cats but little effect on normal motor function.
In our study, postoperative analgesia was significantly better and longer in the midazolam group as demonstrated by its significantly longer time until the first request for analgesia and also the lower need for rescue analgesics. This finding was in accordance with the study of Kim and Lee (
28), who reported that the addition of 1 or 2 mg of intrathecal midazolam prolonged the postoperative analgesic effect of bupivacaine by approximately 2 hours and 4.5 hours, respectively, compared with controls after hemorrhoidectomy and used fewer analgesics in the first 24 hours after surgery. The result suggested a dose-dependent effect of intrathecal midazolam. Similar results were reported by other studies (
29,
30). Prakash et al. concluded that 2 mg intrathecal midazolam provided a moderate prolongation of postoperative analgesia in cesarean patients (
11). Similar observations were reported by previous studies (
12,
31). Other than cesarean patients, similar observations were also provided for patients undergoing orthopedic and other types of surgeries (
29,
32).
The second observation in our study was that the median peak sensory level (T4) and motor block (bromoge 3) achieved with intrathecal midazolam were faster compared to the control group as reported by Sanwal et al. (
31), who noted that decreasing the dose of bupivacaine to 7.5 mg along with 2 mg of midazolam did not affect the sensory level. Similar observations have been reported by other studies (
33,
34). Further investigations have shown that the addition of midazolam or fentanyl to intrathecal bupivacaine does not alter the peak level of the sensory block (
9,
35,
36). Similar observations were noted in our study.
The third observation that should be considered is the duration of the motor block, which was comparable in both groups (BC: 175.3 ± 20.21 vs. BM: 185.8 ± 39.74). This finding is consistent with the study of Shadangi et al. (
37), whereas Bharti et al. (
9) reported a prolonged motor block in their midazolam group. The result in our study was in accordance with Muller et al., who reported an antispasticity effect of intrathecal midazolam with little effect on normal motor function (
27). The fourth observation in our study was the episodes of hypotension and the associated vasopressor requirement, which were significantly high in the control group compared to the midazolam group. This trend is consistent with studies by Sanwal et al. who reported that this relationship may be due to the bupivacaine-sparing effect of midazolam and concluded that intrathecal midazolam may allow the dose of bupivacaine to be reduced while still providing the same surgical anaesthesia with fewer episodes of bradycardia and hypotension (
31). A similar observation was reported by previous studies (
9,
25,
29). The Apgar score was comparable in both groups at 1, 5, and 10 minutes, which is consistent with the findings of previous studies (
38).
Of note, the incidence of sedation was comparable in both groups. Patients in the midazolam group remained calm with a response to stimulus, which may be attributed to the anxiolytic effect of midazolam. Further, the incidence of nausea and vomiting was also found to be low in the midazolam group. In a study by Salami et al. (
39), adjunct intrathecal midazolam was shown to potentially provide a more prolonged analgesia than opioids alone while also inhibiting their adverse effects, such as nausea and vomiting. A similar observation was reported by other studies (
11,
12). It has been postulated that a possible mechanism for the anti-emetic effect of benzodiazepines could be an action at the chemoreceptor trigger zone, which reduce the synthesis, release, and postsynaptic effect of dopamine (
40). The molecular basis of the specific antiemetic activity of intrathecal midazolam remains to be elucidated.
As noted in our study, shivering was decreased in the midazolam group. The mechanism for this is unclear and has to be determined. Various drugs like tramadol, dexmedetomedine, and magnesium sulfate have been added intrathecally to reduce shivering in caesarean patients (
41-
44). Further studies are recommended on the anti-shivering effect of midazolam.
5.1. Conclusions
Intrathecal midazolam provides significant and effective postoperative analgesia along with stable intraoperative hemodynamics without affecting the level of sensory and motor blocks. Adequate postoperative analgesia can be achieved with minimal side effects using intrathecal midazolam in PIH patients.